Patient selection in high-dose chemotherapy trials: Relevance in high- risk breast cancer

Journal of Clinical Oncology

Volumn 15, Issue 10, 1997, Pages 3178-3184

  García Carbonero, Rocío ^a   Hidalgo, Manuel ^a   Paz Ares, Luis ^a   Calzas, Julia ^a   Gómez, Henry ^a   Guerra, Juan Antonio ^a   Hitt, Ricardo ^a   Hornedo, Javier ^a   Colomer, Ramón ^a   Cortés Funes, Hernán ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; PREDNISONE; TAMOXIFEN; VINCRISTINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MASTECTOMY; PATIENT SELECTION; PRIORITY JOURNAL;

EID: 0343632389     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.10.3178     Document Type: Article

References (28)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or inmune therapy. Lancet 339:1-15, 71-85, 1992
2. Peters W, Ross M, Vredenburg J, et al: High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 11:1132-1143, 1993
3. Peters W, Fay JW, Holland HK, et al: Autologous bone marrow transplantation as adjuvant therapy in primary breast cancer: The American experience. Bone Marrow Transplant 15:254-262, 1995 (suppl 1)
4. Peters WP, Berry D, Vredenburg JJ, et al: Five-year follow-up of high-dose combination alkylating agents with ABMT as consolidation after standard-dose CAF for primary breast cancer involving ≥ 10 axillary lymph nodes (Duke/CALG B 8782). Proc Am Soc Clin Oncol 14:317, 1995 (abstr 933)
5. Gianni A, Siena S, Bregni M, et al: Five-year results of high-dose sequential adjuvant chemotherapy in breast cancer with ≥ 10 positive nodes. Proc Am Soc Clin Oncol 14:90, 1995 (abstr 61)
6. Abeloff MD, Beveridge RA, Donehower RC, et al: Sixteen week dose intense chemotherapy in the adjuvant treatment of breast cancer. JNCI (J Natl Cancer Inst) 82:570-574, 1990
7. Tajima T, Tokuda Y, Kubota M, Mitomi T: Adjuvant chemotherapy supported by autologous bone marrow transplantation in breast cancer. Proc Am Soc Clin Oncol 9:31, 1990 (abstr 116)
8. Somlo G, Doroshow J, Forman S, et al: High-dose doxorrubicin, etoposide, and cyclophospamide with stem cell reinfusion in patients with metastatic or high risk primary breast cancer. Cancer 73:1678-1685, 1994
9. Rahman Z, Frye D, Buzdar A, et al: A retrospective analysis to evaluate the impact of selection process for high-dose chemotherapy on the outcome of patients with metastatic breast cancer. Proc Am Soc Clin Oncol 14:95, 1995 (abstr 78)
10. Bladé J, San-Miguel JF, Fontanillas M, et al: Survival of multiple myeloma patients who are candidates for early high-dose therapy intensification autotransplantation and who were conventionally treated. J Clin Oncol 14:2167-2173, 1996
11. Kaplan EL, Meier P: Non parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
12. Peto R, Peto J: Assymptotically efficient rank invariant test procedures. J R Stat Soc A 35:185-206, 1972
13. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
14. Osborne CK, Clark GM, Ravdin P: Treatment of early stage breast cancer, in Harris JR, Lippman ME, Morrow M, Hellman S (eds): Diseases of the Breast. Philadelphia, PA, Lippincott, 1996, pp 487-585
15. Attal M, Huguet F, Schlaifer D, et al: Intensive combined therapy for previously untreated aggresive myeloma. Blood 79:1130-1136, 1992
16. Buzzoni R, Bonadona G, Valagussa P, et al: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 19:2134-2140, 1991
17. Buzdar AU, Kau AU, Hortobagyi GN, et al: Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer 69:448-45, 1992
18. Tormey DC, Weinberg VE, Holland JF, et al: A randomized trial of five and three drug chemotherapy and chemoinmunotherapy in women with operable node positive breast cancer. J Clin Oncol 1:138-145, 1983
19. Perloff M, Norton L, Korzun AH, et al: Postsurgical adjuvant chemotherapy of stage II breast carcinoma with or without crossover to a non-cross-resistant regimen: A Cancer and Leukemia Group B Study. J Clin Oncol 14:1589-1598, 1996
20. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
21. Crump M, Goss PE, Prince M, et al: Outcome of extensive evaluation before adjuvant therapy in women with breast cancer and ten or more positive axillary lymph nodes. J Clin Oncol 14:66-69, 1996
22. Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-14, 1981
23. Adami HO, Birgitta M, Holmberg L, et al: The relation between survival and age at diagnosis in breast cancer. N Engl J Med 315:559-563, 1986
24. Chung M, Chang HR, Bland KI, et al: Younger women with breast cancer have a poorer prognosis than older women. Cancer 77:97-103, 1996
25. Vincent MD, Powles TJ, Sweet R, et al: An analysis of possible features of long-term survivors of metastatic breast cancer. Eur J Cancer Clin Oncol 22:1059-1065, 1986
26. Ragaz J, Jackson S, Le N, et al: Can adjuvant locoregional radiotherapy reduce systemic recurrences in stage I-II breast cancer patients? Recurrence analysis of the British Columbia randomized trial. Proc Am Soc Clin Oncol 15:121, 1996 (abstr 150)
27. Arriagada R, Rutqvist LE, Matsson A, et al: Adequate locoregional treatment for early breast cancer may prevent secondary dissemination. J Clin Oncol 13:2869-2878, 1995
28. Dombernowsky P, Hansen PS, Mouridsen HT, et al: Randomized trial of adjuvant CMF + radiotherapy vs CMF alone + tamoxifen in pre- and postmenopausal stage II breast cancer. Ann Oncol 5:2, 1994 (abstr 4)